Johnson & Johnson’s agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines.
Intra-Cellular Therapies reported its drug Caplyta met the main and secondary goals in the first of three pivotal studies in major depressive disorder. Success in two of them could support expanding the label of the drug, which is currently approved in schizophrenia and bipolar depression.
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.
The company said the decision to cancel the advisory committee meeting for lumateperone was made so the agency would have additional time to review information the firm had provided regarding the drug.
The company's shares fell more than 20 percent Monday on data from the trials of lumateperone, but an analyst wrote that the reason for the high placebo response rate that led to one trial's failure remains unclear.